CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

First Tracks Biotherapeutics, Inc.

TRAX
$1.37BSmall Cap

Next catalyst

Phase 3Feb 28, 2027in 98 days

Phase 3 — zipalertinib

Get an email about TRAX's next catalysts

Track First Tracks Biotherapeutics (TRAX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 2 past

Phase 3Next

Phase 3 — zipalertinib

Feb 28, 2027

For cancer. Taiho Pharmaceutical and Cullinan Therapeutics' zipalertinib successfully completed a Phase 3 trial and is currently under FDA review with a decision expected by February 2027, positioning the asset for first-line cancer competition.

Source

How TRAX's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO
Drug Pipeline

No drugs found in this phase.

cancer

2 drugs in this indication

advanced GEP-NETs

1 drug in this indication

stem cell transplant preparation

1 drug in this indication

First-line unresectable hepatocellular carcinoma (HCC)

1 drug in this indication

First-line consolidation therapy in MRD-positive large B-cell lymphoma

1 drug in this indication

Alexander disease in pediatric and adult patients

1 drug in this indication

Alexander disease

1 drug in this indication

spinal cord injuries

1 drug in this indication

cholangiocarcinoma with acquired FGFR inhibitor resistance

1 drug in this indication

BCL (B-cell lymphoma)

1 drug in this indication

early-onset disc problems

1 drug in this indication

relapsed/refractory multiple myeloma

1 drug in this indication

weight loss

1 drug in this indication

senescent cell accumulation, aging-related metabolic dysfunction

1 drug in this indication

hematologic malignancy (follicular lymphoma)

1 drug in this indication

soft tissue sarcoma

1 drug in this indication

Pulmonary heart valve for pediatric patients with congenital pulmonary valve disease

1 drug in this indication

symptomatic HFpEF (heart failure with preserved ejection fraction)

1 drug in this indication

dermatomyositis in adults

1 drug in this indication

Recurrent atypical teratoid/rhabdoid tumor (CNS tumor)

1 drug in this indication

Recurrent urinary tract infections (UTIs)

1 drug in this indication

pancreatic cancer

1 drug in this indication

Mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) in pediatric patients

1 drug in this indication

Local anesthesia, nerve blocks, pain management

1 drug in this indication

Recurrent respiratory papillomatosis (RRP) in adults

1 drug in this indication

Sickle cell disease

1 drug in this indication

PRKAG2 syndrome

1 drug in this indication

First-line metastatic triple-negative breast cancer

1 drug in this indication

nonsense mutation Alport syndrome

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

When is First Tracks Biotherapeutics, Inc.'s next FDA catalyst?→

First Tracks Biotherapeutics, Inc.'s (TRAX) next tracked catalyst is a Phase 3 readout expected Feb 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track TRAX biotech catalysts?→

Add TRAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow First Tracks Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply